Home/Pipeline/NGM831 (MK-3655)

NGM831 (MK-3655)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 2bActive (Merck-led)

Key Facts

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase

Phase 2b

Status

Active (Merck-led)

Company

NGM Biopharmaceuticals

About NGM Biopharmaceuticals

NGM Biopharmaceuticals is a clinical-stage biotech firm focused on discovering and developing first-in-class therapeutics through its integrated biology platform. A key achievement was a major, long-term collaboration with Merck & Co., which provided significant validation and funding, though it was restructured in 2023 to return full rights to NGM for most assets. The company's strategy centers on deeply understanding novel biological pathways, such as GDF15, to address large-market indications with high unmet need, including hyperemesis gravidarum and cancer cachexia. NGM aims to de-risk development through rigorous translational science and patient stratification.

View full company profile

Therapeutic Areas

Oncology Metabolic Ophthalmology Gastroenterology

Other Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs

Drug	Company	Phase	Status
Pegozafermin (BIO89-100)	89bio	Phase 3	Active
Icosabutate	NorthSea Therapeutics	Phase 3	Active
Oxy210	MAX BioPharma	Preclinical	Active
NA-941	Biomed	Phase 2A	Active
PRO-MSH-001	ProdIgY Biotech	Discovery	Active
Undisclosed MASH Program	Syndya Therapeutics	Discovery	Active
Partnered Program	Cellarity	Pre-clinical	Active
Lanifibranor	Hepalys	Phase 1	Active (Japan development program)
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
ION224 (IONIS-DGAT2Rx)	Ionis Pharmaceuticals	Phase 2b	Active
ALG-055009	Aligos Therapeutics	Phase 2	Active
CM-101	Chemomab Therapeutics	Phase 2a	Completed